Grufity logo
Grufity logo
SCYX

SCYX - SCYNEXIS Inc Stock Price, Fair Value and News

$4.11+0.02 (+0.49%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

76/100

SCYX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

76/100

SCYX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SCYX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SCYX Price Action

Last 7 days

-7.6%

Last 30 days

-30.6%

Last 90 days

-44.2%

Trailing 12 Months

-36.4%

SCYX RSI Chart

SCYX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SCYX Valuation

Market Cap

253.8M

Price/Earnings (Trailing)

-10.35

Price/Sales (Trailing)

12.32

EV/EBITDA

-25.2

Price/Free Cashflow

-42.88

SCYX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SCYX Fundamentals

SCYX Revenue

Rev. Growth (Yr)

1.8K%

Rev. Growth (Qtr)

5.5K%

SCYX Earnings

Earnings (TTM)

-24.5M

Earnings Growth (Yr)

-295.08%

Earnings Growth (Qtr)

-273.76%

SCYX Profitability

Operating Margin

28.56%

EBT Margin

-41.79%

Return on Equity

-59.35%

Return on Assets

-31.58%

Free Cashflow Yield

-2.33%

SCYX Investor Care

Shares Dilution (1Y)

1172.19%

Diluted EPS (TTM)

-0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20252.6M3.3M2.9M20.6M
2024106.0M71.9M37.8M3.7M
202338.9M72.6M106.4M140.1M
20221.8M3.1M4.2M5.1M
20216.7M8.9M11.0M13.2M
2019256.5K249.5K2.4M4.6M
2018256.5K256.5K256.5K256.5K
2017257.0K257.0K257.0K256.5K
2016256.0K256.0K256.0K257.0K
20151.3M1.3M1.3M257.0K
2014---1.3M
2013----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About SCYNEXIS Inc

SCYX
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
 CEO
 WEBSITEscynexis.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES36

SCYNEXIS Inc Frequently Asked Questions

SCYX is the stock ticker symbol of SCYNEXIS Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of SCYNEXIS Inc is 253.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, SCYX's PE ratio (Price to Earnings) is -10.35 and Price to Sales (PS) ratio is 12.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCYX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, SCYNEXIS Inc has provided -0.321 (multiply by 100 for percentage) rate of return.